UNITED STATESSECURITIES AND EXCHANGE COMMISSION ~~COMMISSIONWashington~~Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-~~16UNDER~~16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~October~~November 2007

Commission File No. 0-29328

ADVANCED PROTEOME THERAPEUTICS CORPORATION
(Translation of registrant's name into English)

BioSquare, 650 Albany Street, Boston, MA 02118 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [ ]

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes [ ] No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

SUBMITTED HEREWITH

Exhibits

99.1	~~Notice~~News ~~regarding~~Release ~~Change~~dated ofJuly ~~Auditor~~11, ~~pursuant~~2007 to– ~~National~~APC ~~Instrument~~Grants ~~51-102~~Stock Options
99.2	~~Letter~~News Release dated ~~October~~July 1024, 2007 ~~from~~- Advanced Proteome Therapeutics ~~Corporation~~Inc. meets Milestone Designed to ~~each~~Facilitate ofthe ~~Davidson~~Enhancement &of ~~Company~~Therapeutic ~~LLP~~Properties ~~and~~of ~~BDO~~Commercially ~~Dunwoody~~Viable ~~LLP~~Proteins
99.3	~~Letter~~Notice ~~dated~~of ~~October~~Meeting ~~10,~~and ~~12007~~Record ~~from~~Date ~~Davidson~~dated &October ~~Company~~30, ~~to the British Columbia and Alberta Securities Commissions~~2007
99.4	Letter dated October 12, 2007 from BDO Dunwoody to the British Columbia and Alberta Securities Commissions

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ADVANCED PROTEOME THERAPEUTICS CORPORATION

Date: ~~October~~November 16, 2007

/s/ Alexander (Allen) ~~Krantz________________ Name~~Krantz________________Name: Alexander (Allen) ~~Krantz Title~~ KrantzTitle: President and Chief Executive Officer

ADVANCED ~~Exhibit~~PROTEOME ~~99.1~~THERAPEUTICS CORPORATION

~~ADVANCED~~ NEWS ~~PROTEOME~~RELEASE ~~THERAPEUTICS CORPORATION(the “Company”)~~

~~NOTICE REGARDING CHANGE OF AUDITOR OF A REPORTING ISSUER~~ ~~GIVENPURSUANT~~APC TOGrants ~~NATIONAL~~Stock ~~POLICY~~Options ~~NI 51 – 102~~

~~October~~ Vancouver 10B.C., July 11, 2007, Advanced Proteome Therapeutics Corporation (APC: TSX-V) (the “Company”) announces that, in accordance with the Company’s stock option plan, it has granted to certain of its directors and employees incentive stock options to purchase up to an aggregate of 370,000 common shares exercisable on or before July 10, 2012 at a price of $0.35 per share. The option grant is subject to board approval.

~~NOTICE~~ Advanced isProteome ~~hereby~~Therapeutics ~~given~~Inc. ~~that~~features ~~effective~~a ~~October~~technology ~~10,~~focused ~~2007 Davidson~~on &the ~~Company,~~redevelopment ~~Chartered~~and ~~Accountants,~~rapid ~~have~~commercialization ~~resigned~~of protein therapeutics and has established laboratory operations at the ~~request~~BioSquare ofDiscovery and Innovation Center on the campus of the ~~Company~~Boston asUniversity School of Medicine. The technology will be targeted initially for the ~~Auditor~~creation of ~~the~~improved ~~Company~~versions ~~and~~of ~~that~~suboptimal ~~BDO~~human ~~Dunwoody,~~protein ~~Chartered Accountants~~pharmaceuticals with established markets. For further information about APC and APT Inc., contact ~~have~~Encompass ~~been~~Communications ~~appointed~~Inc. asat ~~the~~604.630.0770 ~~Auditor~~or oftoll ~~the~~free ~~Company~~at 877 566 6592.

~~There have been no reservations in the Auditors’ Reports for~~ ~~the~~ON ~~audits~~BEHALF ~~for~~OF ~~the~~THE ~~two~~BOARD most recently completed fiscal years. In the opinion of the Company, prior to the appointment of BDO Dunwoody, Charted Accountants, there were no reportable events. A reportable event is an occurrence in the relationship between the reporting issuer and the Former or Successor Auditor which may have been a contributing factor to the change.

~~The~~ Alexander ~~contents~~(Allen) ofKrantz ~~this~~ President ~~Notice~~& ~~have been reviewed by the Audit Committee.~~CEO

On The ~~behalf~~TSX ofVenture Exchange does not accept responsibility for the ~~Board,ADVANCED~~adequacy ~~PROTEOME~~or ~~THERAPEUTICS CORPORATION~~accuracy of this release.

~~/s/~~ADVANCED ~~Alexander~~PROTEOME ~~(Allen)~~THERAPEUTICS ~~Krantz~~CORPORATION ~~ALEXANDER (ALLEN) KRANTZ CFO~~

~~Exhibit~~NEWS ~~99.2~~RELEASE

~~October~~Advanced ~~16,~~Proteome ~~2007~~Therapeutics Inc. meets Milestone Designed to Facilitate the Enhancement of Therapeutic Properties of Commercially Viable Proteins

~~DAVIDSON~~Vancouver, &BC, ~~COMPANY~~July ~~LLPChartered~~24, ~~Accountants609~~2007 Advanced Proteome ~~Granville~~Therapeutics ~~Street~~Corporation ~~Vancouver,~~(APC: BCTSX-V) ~~V7Y~~wishes ~~1G6~~to announce that the Company has achieved its first milestone of synthesizing a large library of molecules that will be used for making specific connections to target proteins. The ability to site-specifically connect entities to therapeutic proteins is an important technological step for enabling enhancements in their therapeutic properties.

-Delivery of protein therapeutics often requires frequent injections because of low activity or rapid clearance, thereby placing a burden on patients and -caregivers. The ability to make attachments of entities that increase and prolong the activity of proteins, thus allowing reduced frequency of administration is regarded as key to improved therapeutic proteins.

~~BDO~~APC’s’s ~~Dunwoody~~kinetic ~~LLP1~~labeling ~~City~~library ~~Centre~~is ~~Drive,~~likely ~~Suite~~to ~~1700Mississauga~~represent an upper limit for screening proteins for site-specific attachments and is the largest library of its type prepared to date. It is noteworthy that despite its structural diversity and the large number of members that are parceled into each of several pools that can be individually tested, ~~Ontario~~the ~~L5B~~library is ~~1M2~~stable and can be manipulated and stored conveniently. It contains many thousands of molecules of various shapes and sizes that are capable of connecting to a protein. The library matches the shapes of its members to complementary shapes on the protein surface and then initiates a bond or connection. The presence of sites on the protein surface that match up to individual members of the library and form specific connections can be revealed by sophisticated analytical techniques. Such sites provide a basis for the attachment of entities that have proven ability to enhance the therapeutic properties of proteins.

~~Dear~~The ~~Sirs/Madam:~~Company has selected an initial target protein with an established market in the billion dollar range for calibrating and optimizing our screening protocol. Our initial focal point is the rapid and specific attachment of entities to commercially viable proteins that have the potential for improving their therapeutic properties. The current emphasis of our efforts is to demonstrate the power of the technology and its great speed relative to the competition in identifying promising drug-conjugates, through its universality, and rapid screening protocols that are conducted on the order of days.

~~RE:~~The ~~Change~~specific attachment of ~~Auditor~~a defined entity to a target protein to create a new substance constitutes a new chemical entity (NCE). These NCEs can be protected for 17 years from the date that a patent is approved. Consequently, improvements in the properties of ~~ADVANCED~~therapeutic ~~PROTEOME~~proteins by ~~THERAPEUTICS~~chemical modification to yield NCE’s have potentially great commercial value ~~CORPORATION~~because of their extended patent life.

WeIncreasing ~~advise that~~competition, onescalating ~~the~~development costs ~~advice~~and ofhigh ~~the~~financial ~~Audit~~expectations ~~Committee~~put ~~of Advanced~~pressure ~~Proteome~~on ~~Therapeutics~~the ~~Corporation~~biopharmaceutical industry ~~(the~~to ~~“Company”),~~increase the ~~Board~~size ~~of Directors~~and value of ~~the~~their ~~Company~~product ~~resolved~~portfolios. ~~on October 10~~In response, ~~2007~~pharmaceutical ~~that~~and ~~consequent~~biotechnology ~~upon~~companies ~~the resignation~~are ofconstantly ~~Davidson~~seeking &ways to ~~Company,~~develop ~~Chartered~~more ~~Accountant,~~new atproducts ~~the~~and/or ~~request~~extend of the ~~Company,~~life ascycles ~~auditor~~ of ~~the~~established products. ~~Company~~Chemical ~~effective~~modification ~~October~~strategies ~~10,~~offer ~~2007,~~effective ~~BDO~~ways ~~Dunwoody,~~to extend ~~Chartered~~product ~~Accountants,~~life ~~have~~cycles ~~been~~by ~~appointed~~enabling asimproved ~~auditor~~therapeutic value of ~~the~~current ~~Company to hold~~products ~~office~~through ~~until~~ the ~~next~~development ~~annual meeting~~ of ~~the~~NCEs ~~Company~~that atafford athe ~~remuneration~~prospects toof bespeedy market ~~fixed~~acceptance, bylarge ~~the~~market ~~directors~~share ofand ~~the~~extended ~~Company~~market lifetimes.

~~Accordingly~~Innovative companies, ~~pursuant~~such as APC, that are trying to ~~National~~generate ~~Instrument~~NCE’s ~~51-102~~have two options before them. They can plan a clinical trial ~~(“Instrument”)~~on their own while seeking regulatory approval, weor ~~now~~license ~~enclose:~~the NCE to another company. In the latter option, innovative companies can avoid the expensive and lengthy process of clinical trials, as the licensee company would be conducting further clinical trials and subsequently launching the drug. Companies adopting this model of business are often able to generate high margins as they can command a large one-time payment for the NCE in addition to entering into a revenue sharing agreement with the licensee company.

~~(a)~~About ~~Notice of Change of Auditor (b) a form of Auditor’s Letter for Davidson & Company, Charted Accountant and (c) a form of Auditor’s Letter for BDO Dunwoody, Chartered Accountants~~APC.

InAdvanced ~~accordance~~Proteome ~~with~~Therapeutics ~~the~~Inc.has ~~provisions~~established operations ofat ~~the~~650 ~~Instrument~~Albany Street, weSuite ~~request that~~113, ~~each~~X ofBuilding, ~~you~~BDIC, ~~furnish~~Boston, usMA ~~with~~02118 and ahas ~~letter~~begun ~~stating~~implementing ~~whether,~~its ~~based~~R&D onplan ~~your~~through ~~present knowledge~~its subsidiary, ~~you~~Advanced Proteome ~~agree~~Therapeutics ~~with~~Inc. ~~the~~APC’s ~~information~~primary ~~contained~~corporate inprimary ~~the~~mission ~~Notice.~~is Ifto ~~you agree~~apply ~~with~~its ~~all~~proprietary ~~the~~drug ~~statements~~delivery inand ~~the~~drug ~~Notice~~redevelopment technologies to produce new, ~~you~~improved ~~may~~versions ~~wish~~of totherapeutic ~~use~~proteins and pioneer the ~~attached~~emerging ~~form~~field of ~~Auditors’~~protein-site ~~Letters~~targeting. The market for therapeutic proteins is expected to surpass ~~reply.~~more Ifthan ~~you~~50 ~~disagree~~Billion ~~with~~USD ~~any~~by ~~statement~~the inyear 2010 and is the ~~Notice,~~fastest growing ~~your~~segment ~~reply~~of ~~should~~the sopharmaceutical ~~state~~market. ~~and~~Future ~~specify~~growth ~~your~~however ~~reasons~~depends largely on the industry overcoming a number of hurdles, including drug delivery challenges.

~~Page~~For 2further information about APC and APT Inc., contact Encompass Communications Inc. at 604.630.0770 or toll free at 877 566 6592.

~~Please~~ON ~~ensure~~BEHALF ~~that~~OF ~~you~~THE ~~address~~BOARD ~~your letters to the Securities Commission in British Columbia and Alberta and return them to us within 10 days after the date of the Notice.~~

~~Yours~~Alexander ~~truly,~~(Allen) Krantz President & CEO

~~ADVANCED~~Certain statements ~~PROTEOME~~contained ~~THERAPEUTICS~~in ~~INC~~this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

/These statements reflect management's/ ~~Alexander~~current ~~(Allen)~~beliefs ~~Krantz~~and are based on information currently available to ~~Alexander~~management. ~~(Allen)~~Certain ~~Krantz~~material factors or assumptions are applied in making ~~President~~forward-looking statements, ~~CEO~~and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: APC’s early stage of development, lack of product revenues and ~~CFO~~history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in APC's filings with Canadian securities regulatory authorities, as well as APC's ability to anticipate and manage the risks associated with the foregoing. APC’s cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on APC's forward-looking statements to make decisions with respect to APC, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

~~Exhibit~~These 99risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements.3 Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, APC cannot provide assurance that actual results will be consistent with these forward-looking statements. APC undertakes no obligation to update or revise any forward-looking statement.

The ~~Exhibit~~TSX 99Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.4

~~October~~Computershare 12Trust Company of Canada 510 Burrard Street, ~~2007~~3rd floor Vancouver, BC V6C 3B9 Tel: 604.661.9400 Fax: 604.661.9401

~~Alberta~~October ~~Securities Commission4th Floor300 – 5th Avenue S.W.Calgary~~30, AB2007 ~~T2P 3C4~~

-Dear Sirs: All applicable Exchanges and -Commissions Subject: ADVANCED PROTEOME THERAPEUTICS CORPORATION

~~British~~We ~~Columbia~~advise ~~Securities~~the ~~Commission701~~following ~~West~~with ~~Georgia~~respect to the upcoming Meeting of ~~StreetVancouver,~~Shareholders BCfor ~~V7Y~~the ~~1L2~~subject Corporation:

Dear Sirs/Mesdames:

1.	Meeting Type	: Annual General Meeting
2.	CUSIP/Class of Security entitled to receive notification	: 007628100/CA0076281009/COMMON
3.	CUSIP/Class of Security entitled to vote	: 007628100/CA0076281009/COMMON
4.	Record Date for Notice	: 03 Dec 2007
5.	Record date for Voting	: 03 Dec 2007
6.	Beneficial Ownership determination date	: 03 Dec 2007
7.	Meeting Date	: 14 Jan 2008
8.	Meeting Location	: TBA

~~Re:~~Sincerely, ~~Change of Auditor of ADVANCED PROTEOME THERAPEUTICS CORPORATION (the “Company”)~~

~~This~~“Brian ~~letter~~Kim” isMeeting ~~provided~~SpecialistClient ~~pursuant~~Services Department toTel: ~~National Policy No~~604.661.9400 31Ext ~~of the~~4139 ~~Canadian~~Fax: ~~Securities Administrators in connection with the change of auditors of the Company~~604.661.9401

We acknowledge receipt of a Notice of Change of Auditor (the “Notice”) dated October 10, 2007 given by the Company, to ourselves and Davidson & Company, Chartered Accountants. Based on our knowledge of such information at this time, we are in agreement with the statements contained in such Notice.

Yours truly,

(signed) “BDO Dunwoody LLP”

BDO Dunwoody LLP, Licensed Public Accountants

cc: Allen Krantz, Advanced Proteome Therapeutics Corporation

Filing Compare · Advanced Proteome Therapeutics CORP